Report overview
The global Meglinitide market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Repaglinide Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Meglinitide include Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company and GSK Plc, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Meglinitides are the agents used to treat type 2 diabetes. They act same as ?-cell receptor as sulphonylureas, but have a different chemical structure. They are novel class of non-sulfonylurea insulin secretagogues characterized by very rapid onset and abbreviated duration of action. They act by stimulating pancreas to release insulin in response to meal. In functioning pancreatic beta cells, it also closes ATP-dependent potassium dependent channels. Due to this depolarization of beta cells, opening of calcium channels resulting in influx of calcium and Increased intracellular calcium induces insulin secretion.
This report aims to provide a comprehensive presentation of the global market for Meglinitide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meglinitide. This report contains market size and forecasts of Meglinitide in global, including the following market information:
Global Meglinitide Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Meglinitide Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Meglinitide companies in 2023 (%)
We surveyed the Meglinitide manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Meglinitide Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Meglinitide Market Segment Percentages, by Type, 2023 (%)
Repaglinide
Nateglinide
Other
Global Meglinitide Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Meglinitide Market Segment Percentages, by Application, 2023 (%)
Type II Diabetes
Others
Global Meglinitide Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Meglinitide Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Meglinitide revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Meglinitide revenues share in global market, 2023 (%)
Key companies Meglinitide sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Meglinitide sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
F. Hoffmann-La Roche Ltd
Mylan N.V
Fresenius Kabi AG
Hikma Pharmaceuticals PLC
Novartis AG
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
GSK Plc
Bayer AG
Sun Pharmaceutical Industries Ltd
Novartis AG
Lupin
Cipla Inc
Aurobindo Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Meglinitide, market overview.
Chapter 2: Global Meglinitide market size in revenue and volume.
Chapter 3: Detailed analysis of Meglinitide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Meglinitide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Meglinitide capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
